 Home > Medical News > Latest Medical News > Concord Kirin Moglizumab Injection is planned to be included in the priority review

Concord Kirin Moglizumab Injection is planned to be included in the priority review

 Last Update: 2021-09-06
 Source: Internet
 Author: User

Tags

united states corporation

food united states

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On July 19, the CDE website announced that Mogamulizumab injection (mogamulizumab) was planned to be included in the priority review

The proposed indication for the drug is adult patients with mycosis fungoides (MF) or Sezari syndrome (SS) who have received at least one systemic treatment in the past

Moglizumab is a CCR4 targeting antibody that has been approved by the FDA for breakthrough therapy and priority review, and has been approved for marketing in the United States

Mogamulizumab (KW-0761) is a humanized CC chemikon receptor 4 (CCR4) monoclonal antibody developed by Kyowa Hakko Kirin

In an open-label, multi-center, randomized phase 3 trial called MAVORIC, a total of 372 patients with mycosis fungoides and Sezari syndrome received mogamulizumab or control drugs

Based on the results of this research, the FDA approved mogamulizumab in August 2018 to treat adult patients with relapsed or refractory mycosis fungoides or Sezari syndrome who have received at least one systemic therapy

Content source: CDE, Pharmaceutical Guanlan

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.